Brain Metastases News and Research

RSS

Varian Medical Systems introduces RapidArc radiotherapy technology in Finland

Cancer patients in Finland have gained access to more advanced treatments with the introduction of RapidArc® radiotherapy technology from Varian Medical Systems at the only private radiotherapy clinic in the Nordic region.

15 Dec 2009

Texas researchers identify new detection method for circulating tumor cells

Circulating metastatic breast cancer cells can lose their epithelial receptors, a process that enables them to travel through the bloodstream undetected, according to research from The University of Texas M. D. Anderson Cancer Center.

14 Dec 2009

New brain metastases treatment guidelines

New treatment guidelines for patients with brain metastases are now available from the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS).

10 Dec 2009

TGen scientists win $1,000 prize for best scientific paper presented at BIBM09

A team of scientists at the Translational Genomics Research Institute (TGen) won a $1,000 prize for best scientific paper presented at BIBM09, a premier bioinformatics and biomedicine conference.

3 Dec 2009

First evidence-based, multidisciplinary treatment guidelines for brain metastases patients to be published

Anthony Asher, MD, FACS, of Carolina Neurosurgery & Spine Associates in Charlotte, NC, has co-authored the first evidence-based, multidisciplinary treatment guidelines for brain metastases patients. These guidelines were recently presented at the Congress of Neurological Surgeons 2009 Annual Meeting in New Orleans, and were developed over the last year by a 20-member panel from various medical specialties.

11 Nov 2009

FDA approves SPA Protocol Amendment for Lucanix Phase III clinical trial

NovaRx Corporation announced today that the Company has successfully negotiated and received FDA approval for a Special Protocol Assessment (SPA) Protocol Amendment to the pivotal Lucanix® Phase III clinical trial in patients with Non-Small Cell Lung Cancer (NSCLC).

4 Nov 2009

Non-small cell lung cancer patients who undergo PCI decrease their risk of developing brain metastases

Patients with non-small cell lung cancer treated with preventative brain radiation (called prophylactic cranial irradiation or PCI), significantly decrease their risk of developing brain metastases (cancer spread in the brain) by more than 50 percent (from 18 percent to 8 percent), compared to those who did not receive the treatment, according to a randomized study presented at the plenary session November 2, 2009, at the 51st Annual Meeting of American Society for Radiation Oncology (ASTRO).

4 Nov 2009

Advanced equipment targets radiation to specific areas in the brain

Radiation oncologists at Rush University Medical Center are intent on finding ways to avoid damage to the critically important hippocampus and limbic circuit of the brain when cranial radiation is required to treat existing or potential metastatic cancers.

4 Nov 2009

New study to assess preventative brain radiation therapy for lung cancer patients

A new study is taking a closer look at the benefits versus risks for lung cancer patients to undergo preventative brain radiation therapy as a means to stop cancer from spreading to the brain.

3 Nov 2009

Patients with non-small cell lung cancer treated with PCI decrease their risk of developing brain metastases

3 Nov 2009

Highlights of new cancer research to be presented at 51st ASTRO Annual Meeting

The following are highlights of new cancer research being presented at the American Society for Radiation Oncology's (ASTRO) 51st Annual Meeting on November 1-5, 2009, in Chicago.

29 Oct 2009

New significant tool to improve the quality of care for patients with brain tumors released

While the nation is debating how best to reform healthcare, the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) announce a new significant tool to improve the quality of care for patients who suffer from brain tumors.

27 Oct 2009

Elekta to demonstrate stereotactic solutions at the 2009 CNS Annual Meeting

At the 2009 Congress of Neurological Surgeons (CNS) Annual Meeting, October 24-28 in New Orleans, Louisiana, Elekta will demonstrate how its line of stereotactic solutions expand treatment capabilities and bring new hope for patients presenting serious conditions.

From Elekta 24 Oct 2009

Angiochem reports Phase 1/2 efficacy study results of ANG1005 for treating brain cancer

Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.

19 Oct 2009

Angiochem announces results of Phase 1 /2 clinical trials of ANG1005

19 Oct 2009

Stereotactic Radiosurgery for metastatic brain tumors reduces risks of learning and memory problems

Cancer patients who receive stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT) for the treatment of metastatic brain tumors have more than twice the risk of developing learning and memory problems than those treated with SRS alone, according to researchers at The University of Texas M. D. Anderson Cancer Center.

7 Oct 2009

US Treasury Department clears YM BioSciences' nimotuzumab clinical program extension

YM BioSciences Inc. a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported operational and financial results for its fiscal year end, ended June 30, 2009.

25 Sep 2009

Nimotuzumab drug approved for Mexican distribution

YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that nimotuzumab has been approved for marketing in Mexico.

17 Sep 2009

Hexokinase 2 gene highly expressed in brain metastasis in breast cancer patients

Researchers at the National Cancer Institute have identified a gene that may play a role in breast cancer metastasis to the brain, according to a report in Molecular Cancer Research, a journal of the American Association for Cancer Research.

2 Sep 2009

Sunitinib shows promise for advanced kidney cancer patients with poor prognosis

Sunitinib prolongs progression-free and overall survival, and is safe and well tolerated in advanced kidney cancer (metastatic renal cell carcinoma) patients with a poor prognosis such as the elderly and those whose cancer has spread to the brain, finds an Article published Online First (www.thelancet.com) and in the August edition of The Lancet Oncology.

16 Jul 2009

Brain Metastases News and Research

Varian Medical Systems introduces RapidArc radiotherapy technology in Finland

Texas researchers identify new detection method for circulating tumor cells

New brain metastases treatment guidelines

TGen scientists win $1,000 prize for best scientific paper presented at BIBM09

First evidence-based, multidisciplinary treatment guidelines for brain metastases patients to be published

FDA approves SPA Protocol Amendment for Lucanix Phase III clinical trial

Non-small cell lung cancer patients who undergo PCI decrease their risk of developing brain metastases

Advanced equipment targets radiation to specific areas in the brain

New study to assess preventative brain radiation therapy for lung cancer patients

Patients with non-small cell lung cancer treated with PCI decrease their risk of developing brain metastases

Highlights of new cancer research to be presented at 51st ASTRO Annual Meeting

New significant tool to improve the quality of care for patients with brain tumors released

Elekta to demonstrate stereotactic solutions at the 2009 CNS Annual Meeting

Angiochem reports Phase 1/2 efficacy study results of ANG1005 for treating brain cancer

Angiochem announces results of Phase 1 /2 clinical trials of ANG1005

Stereotactic Radiosurgery for metastatic brain tumors reduces risks of learning and memory problems

US Treasury Department clears YM BioSciences' nimotuzumab clinical program extension

Nimotuzumab drug approved for Mexican distribution

Hexokinase 2 gene highly expressed in brain metastasis in breast cancer patients

Sunitinib shows promise for advanced kidney cancer patients with poor prognosis

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News